Table 1.
Risk factors of patients at recruitment in relation to AAA thrombus volumes.
| Characteristic | Total | Thrombus <25.0cm3 | Thrombus ≥25.0cm3 | p-value |
|---|---|---|---|---|
| Patients | 98 | 43 | 55 | |
| Age, years | 73 (67–77) | 72 (67–75) | 74 (68–78) | 0.245 |
| Male | 75 (76.5) | 28 (65.1) | 47 (85.5) | 0.029 |
| Follow-up, years | 3.0 (2.0–3.6) | 3.2 (2.0–3.7) | 2.8 (1.9–3.4) | 0.358 |
| Maximum AAA axial diameter, mm | 47.2 (34.9–54.6) | 34.4 (32.2–42.6) | 52.8 (49.5–58.1) | <0.001 |
| Body Mass Index, weight(kg)/height(m)2 | 28.2 (25.0–30.8) | 28.7 (25.6–32.0) | 27.8 (24.5–30.3) | 0.150 |
| Intermittent claudication | 29 (29.6) | 18 (41.9) | 11 (20.0) | 0.026 |
| Diabetes mellitus | 20 (20.4) | 8 (18.6) | 12 (21.8) | 0.803 |
| Ever smoked | 86 (87.8) | 36 (83.7) | 50 (90.9) | 0.357 |
| Hypertension | 75 (76.5) | 33 (76.7) | 42 (76.4) | 1.000 |
| Coronary heart disease | 59 (60.2) | 25 (58.1) | 34 (61.8) | 0.836 |
| Warfarin | 13 (13.3) | 7 (16.3) | 6 (10.9) | 0.552 |
| Aspirin | 62 (63.3) | 27 (62.8) | 35 (63.6) | 1.0 |
| Calcium channel blocker | 24 (24.5) | 13 (30.2) | 11 (20.0) | 0.344 |
| ACE inhibitor | 42 (42.9) | 22 (51.2) | 20 (36.4) | 0.156 |
| Statin | 65 (66.3) | 24 (55.8) | 41 (74.5) | 0.057 |
| Beta blocker | 35 (35.7) | 18 (41.9) | 17 (30.9) | 0.293 |
Continuous results are presented as medians (inter-quartile range) and compared by Mann Whitney U; nominal results are presented as number (%) and are compared by Fisher’s exact test (2-tailed significance).